top of page

Free Biopharma Daily Stock Updates - 01/24/22

$XBI $92.11 | +2.31%


Covid Updates

$SRNE -7.1% Sorrento Receives Purchase Order for 10 Million Covistix Tests From Its Subsidiary Sorrento Mexico for February Delivery in Mexico source

$ANIX -2.6% Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor. source

$ARCT +1.3% Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants. source

$PFE -2.4% & $BNTX +2.4% Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant. source

Pipeline Updates

$MBIO +1.5% Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients source

$DCPH +5.4% Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session source

$ETNB -4.2% 89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH source

$HZNP +0.5% Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). source

$SLNO +17.1% Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome. source

$LYEL +3.8% Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK. source

$CDXS +3.6% Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria. source

$KALV +0.7% KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology. source

$IONS +5.1% Ionis announces eplontersen receives orphan drug designation from U.S. FDA. source

$BLRX BioLineRx Announces Completion of Enrollment of Phase 1/2a Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors. source

$LYRA -0.6% Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients. source

$VKTX -6.6% Viking Therapeutics Announces Clinical Hold on Phase 1b Trial of VK0214 in Patients with X-ALD. source

$CNTB -6.3% Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference. source

$TCRX -5.2% TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies. source

$LTRN +0.2% Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System. source

$SQZ +6.6% SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors. source

$MDWD +3.3% MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds. source

$ERYP -4.7% ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI. source

$OPK -23.8% Pfizer, OPKO receive somatrogon Complete Respoinse Letter for growth hormone deficiency. source

Business Updates

$SPRB -0.4% Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022. source

$ABUS +0.4% Arbutus Announces 2022 Corporate Objectives and Provides Financial Update. source

$ARWR +3.8% Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline. source

$GLSI +27.0% Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year. source


Posted by FS/JM

bottom of page